Former US Food and Drug Administration commissioner Scott Gottlieb's primary focus on chimeric antigen receptor T-cell (CAR-T) products when he was head of the agency involved ensuring such products were safe and effective. Now in his post-commissioner life, it appears he will be broadening his attention even further to include their reimbursement.
Speaking on 10 May at the National Press Club in one of his first public addresses since leaving the agency,...







